Vicuron Pharmaceuticals to Present at the BIO CEO & Investor Conference 2005

Vicuron Pharmaceuticals to Present at the BIO CEO & Investor
Conference 2005 


KING OF PRUSSIA, Pa., Feb. 17  /PRNewswire-FirstCall/ -- Vicuron
Pharmaceuticals Inc. (Nasdaq: MICU; Nuovo Mercato: MICU) today announced that
George F. Horner III, President and Chief Executive Officer, will present at
the 2005 BIO CEO & Investor Conference at 2:00 p.m. Eastern Standard Time on
Thursday, February 24, 2005 at the Waldorf-Astoria in New York City.

To access the live audio broadcast or the subsequent archived recording log on
to http://www.vicuron.com/ and click on the investor relations section. Please
connect to the website several minutes prior to the start of the webcast to
ensure adequate time for any software download that may be necessary. The live
broadcast will be archived for 30 days.

About Vicuron Pharmaceuticals

Vicuron Pharmaceuticals is a biopharmaceutical company focused on discovering,
developing, manufacturing and commercializing vital medicine for seriously ill
patients. The company has two New Drug Applications pending with the U.S. Food
and Drug Administration for its lead products, dalbavancin, a novel intravenous
antibiotic for the treatment of serious Gram-positive infections, and
anidulafungin, a novel antifungal agent.  Vicuron's versatile research engine
integrates industry-leading expertise in functional genomics, natural products
discovery, mechanism-based drug design and combinatorial and medicinal
chemistry.  These approaches are yielding promising novel and next-generation
compounds, many of which are in the later stages of preclinical development. In
addition, the company has research and development collaborations with leading
pharmaceutical companies, such as Novartis and Pfizer.

Forward-Looking Statements

The presentation contains forward-looking statements that predict or describe
future events or trends. The matters described in these forward-looking
statements are subject to known and unknown risks, uncertainties and other
unpredictable factors, many of which are beyond Vicuron's control. Vicuron
faces many risks that could cause its actual performance to differ materially
from the results predicted by its forward-looking statements, including the
possibilities that clinical trials and the results thereof might be delayed or
unsuccessful, that the timing of the filing of any new drug application or any
amendment to a new drug application might be delayed, that clinical trials
might indicate that a product candidate is unsafe or ineffective, that the FDA
might require additional information to be submitted and additional actions to
be taken before it will make any decision, that any filed new drug application
may not be approved by the FDA, that ongoing proprietary and collaborative
research might not occur or yield useful results, that the pipeline may not
yield a new clinical candidate or a commercial product, that a third party may
not be willing to license Vicuron's product candidates on terms acceptable to
it or at all, that competitors might develop superior substitutes for Vicuron's
products or market these competitive products more effectively, that a sales
force may not be developed as contemplated and that one or more of Vicuron's
product candidates may not be commercialized successfully. The reports that
Vicuron files with the U.S. Securities and Exchange Commission contain a fuller
description of these and many other risks to which Vicuron is subject. Because
of those risks, Vicuron's actual results, performance or achievements may
differ materially from the results, performance or achievements contemplated by
its forward-looking statement. The information set forth in the presentation
represents management's current expectations and intentions. Vicuron assumes no
responsibility to issue updates to the forward-looking matters discussed in the
presentation. 

DATASOURCE: Vicuron Pharmaceuticals Inc.



CONTACT:  Dov A. Goldstein, M.D., of Vicuron Pharmaceuticals Inc.,

[phone], or ; or E. Blair Schoeb of WeissComm

Partners, [phone], or , for Vicuron

Pharmaceuticals Inc.; or Aline Schimmel of Burns McClellan Inc.,

[phone], or , for Vicuron Pharmaceuticals Inc.



Web site:  http://www.vicuron.com/ 

Copyright